SCHEMBL1963803

SCHEMBL1963803

COC(=O)c1cccc(CBr)c1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.51
ALDH1A1 P00352 4/20 0.51
PDK1 Q15118 1/20 0.45
PDK2 Q15119 1/20 0.45
PDK3 Q15120 1/20 0.45
PDK4 Q16654 1/20 0.45
TSHR P16473 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HSD17B10 Q99714 2/20 0.43
CFTR P13569 1/20 0.43
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 3/20 0.42
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.42
MAPT P10636 2/20 0.42
MAPK8 P45983 1/20 0.42
MAPK9 P45984 1/20 0.42
MAPK10 P53779 1/20 0.42
NR4A2 P43354 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7268731 0.85 ABL1 (0.44) LMNAALDH1A1PDK1PDK2PDK3
SCHEMBL16955180 0.85 LMNA (0.49) LMNAALDH1A1PDK1PDK2PDK3
SCHEMBL3708333 0.84 TSHR (0.56) ALDH1A1PDK2TSHRHSD17B10KMT2A
SCHEMBL28626456 0.83 PDK1 (0.36) LMNAALDH1A1PDK1PDK2PDK3
SCHEMBL30000533 0.83 PDK1 (0.36) LMNAALDH1A1PDK1PDK2PDK3
SCHEMBL30945155 0.82 ALDH1A1 (0.67) LMNAALDH1A1TSHRSLC6A3HSD17B10
SCHEMBL104703 0.82 ALDH1A1 (0.67) LMNAALDH1A1TSHRSLC6A3HSD17B10
SCHEMBL20377207 0.81 ALDH1A1 (0.53) LMNAALDH1A1TSHRHSD17B10CFTR
SCHEMBL5839700 0.81 ALDH1A1 (0.53) LMNAALDH1A1TSHRSLC6A3HSD17B10
SCHEMBL1760164 0.81 ALDH1A1 (0.53) LMNAALDH1A1TSHRSLC6A3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4650345-A1 HETEROCYCLIC COMPOUND AND USE THEREOF IN MEDICINE Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) 2025-11-19 EP disclosed
WO-2024149242-A1 HETEROCYCLIC COMPOUND AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2024-07-18 WO disclosed
CN-111253404-B Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof 上海医药集团股份有限公司 2023-05-23 CN disclosed
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2022-02-17 US disclosed
EP-3889156-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2021-10-06 EP disclosed
CN-111253404-A Nitrogen-containing heterocyclic compound and composition, preparation method and application thereof 上海医药集团股份有限公司 2020-06-09 CN disclosed
EP-2709990-B1 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer IMPACT THERAPEUTICS INC (CN) 2019-06-12 EP disclosed
US-10316035-B2 Triazolopyridine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2019-06-11 US disclosed
US-10316027-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2019-06-11 US disclosed
US-20180244671-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MEYERS SQUIBB COMPANY (US) 2018-08-30 US disclosed
WO-2011070039-A1 SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 WO disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed
EP-2181987-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-05 EP disclosed
US-7622612-B2 Tricyclic derivatives and their use CHEMTECH RESEARCH INCORPORATION (KR) 2009-11-24 US disclosed
US-7622612-B2 Tricyclic derivatives and their use CHEMTECH RESEARCH INCORPORATION (KR) 2009-11-24 US disclosed
US-20070021427-A1 Novel tricyclic derivatives and their use CHEMTECH RESEARCH INCORPORATION (KR) 2007-01-25 US disclosed
US-20070021427-A1 Novel tricyclic derivatives and their use CHEMTECH RESEARCH INCORPORATION (KR) 2007-01-25 US disclosed
CN-1105701-C Method for preparing substituted benzyl bromides BASF AG (DE) 2003-04-16 CN disclosed
CN-1265639-A Method for preparing substituted benzyl bromides BASF AG (DE) 2000-09-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316035-B2 Triazolopyridine inhibitors of myeloperoxidase EPX, MPO, SERPINB1 LMNA 4467/4885ALDH1A1 79/4885PDK1 1142/4885
US-20180244671-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 LMNA 4467/4885ALDH1A1 79/4885PDK1 1142/4885
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 LMNA 4482/4885ALDH1A1 625/4885PDK1 479/4885
US-10316027-B2 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof PARP1, PARP11, PARP3 LMNA 1322/4885ALDH1A1 88/4885PDK1 103/4885
US-20070021427-A1 Novel tricyclic derivatives and their use NFATC1, IL2, CCL2 LMNA 4574/4885ALDH1A1 2078/4885PDK1 1641/4885
US-20220048915-A1 Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof MAPK11, WEE1, NOS1 LMNA 2598/4885ALDH1A1 3002/4885PDK1 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.